{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:47:00Z","timestamp":1790444820298,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, significantly impairing the quality of life. Bacterial proliferation and inflammation play central roles in the pathogenesis of MGD, creating a vicious cycle of gland obstruction and ocular surface instability. Antibiotics, particularly tetracyclines (e.g. doxycycline and minocycline), and macrolides (e.g. azithromycin and erythromycin), are widely used as adjunctive therapy for moderate-to-severe or refractory MGD. This review conducted a comprehensive literature search of PubMed, focusing on original peer-reviewed articles published in English that reported on the efficacy and\/or safety of oral or topical antibiotics for MGD or blepharitis. Eligible studies were identified using the specific search terms, screened by title and abstract, and selected based on predefined inclusion and exclusion criteria. Relevant data were extracted and synthesized, with an emphasis on randomized controlled trials and comparative studies. The review indicates that both oral and topical antibiotics improve subjective symptoms, tear film stability, ocular surface staining, meibum quality, and lid margin abnormalities in the short term. Oral azithromycin may be at least as effective as doxycycline, with a shorter treatment course and fewer adverse events, while topical azithromycin offers similar or superior efficacy to systemic regimens with reduced systemic exposure. However, benefits are usually limited to active treatment periods, and optimal dosing and duration remain uncertain. Long-term efficacy, safety, risk of resistance, and effects on the ocular microbiome require further investigation. Antibiotics should be used judiciously as part of a comprehensive, individualized management strategy for MGD.<\/jats:p>","DOI":"10.4103\/tjo.tjo-d-25-00109","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:01:29Z","timestamp":1762538489000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Therapies for Meibomian Gland Dysfunction \u2013 The Role of Antibiotics in Meibomian Gland Dysfunction Management"],"prefix":"10.4103","author":[{"given":"Reiko","family":"Arita","sequence":"first","affiliation":[{"name":"Itoh Clinic, Saitama, Japan"},{"name":"Lid and Meibomian Gland Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R1-20260105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III diagnostic methodology","volume":"279","author":"Wolffsohn","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R2-20260105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","article-title":"TFOS DEWS III digest report","volume":"279","author":"Stapleton","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R3-20260105","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":"The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20260105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ajo.2019.02.024","article-title":"Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: The Hirado-Takushima study in Japan","volume":"207","author":"Arita","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R5-20260105","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","article-title":"The international workshop on meibomian gland dysfunction: Report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland","volume":"52","author":"Knop","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-20260105","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":"The international workshop on meibomian gland dysfunction: Report of the subcommittee on management and treatment of meibomian gland dysfunction","volume":"52","author":"Geerling","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20260105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtos.2022.08.010","article-title":"Antibiotic treatment for dry eye disease related to meibomian gland dysfunction and blepharitis \u2013A review","volume":"26","author":"Vernhardsdottir","year":"2022","journal-title":"Ocul Surf"},{"key":"R8-20260105","first-page":"e1","article-title":"Systemic antibiotic treatment for meibomian gland dysfunction-A systematic review and meta-analysis","volume":"102","author":"Ben Ephraim Noyman","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"R9-20260105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS DEWS III management and therapy report","volume":"279","author":"Jones","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R10-20260105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ophtha.2015.10.062","article-title":"Oral antibiotics for meibomian gland-related ocular surface disease: A report by the American Academy of Ophthalmology","volume":"123","author":"Wladis","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20260105","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41433-020-0876-2","article-title":"Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin","volume":"34","author":"Tao","year":"2020","journal-title":"Eye (Lond)"},{"key":"R12-20260105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","article-title":"Topical azithromycin therapy for meibomian gland dysfunction: Clinical response and lipid alterations","volume":"29","author":"Foulks","year":"2010","journal-title":"Cornea"},{"key":"R13-20260105","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","article-title":"The international workshop on meibomian gland dysfunction: Executive summary","volume":"52","author":"Nichols","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20260105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","article-title":"The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction","volume":"19","author":"Yoo","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"R15-20260105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/bjo.2007.133900","article-title":"Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment","volume":"92","author":"Souchier","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R16-20260105","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","article-title":"Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis","volume":"25","author":"Luchs","year":"2008","journal-title":"Adv Ther"},{"key":"R17-20260105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1590\/S0004-27492012000300006","article-title":"Azithromycin 1.5% ophthalmic solution: Efficacy and treatment modalities in chronic blepharitis","volume":"75","author":"Fadlallah","year":"2012","journal-title":"Arq Bras Oftalmol"},{"key":"R18-20260105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ajo.2012.06.009","article-title":"Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction","volume":"154","author":"Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R19-20260105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bjophthalmol-2014-305410","article-title":"Oral azithromycin versus doxycycline in meibomian gland dysfunction: A randomised double-masked open-label clinical trial","volume":"99","author":"Kashkouli","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R20-20260105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2017.0095","article-title":"Comparison of the clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis","volume":"34","author":"Yildiz","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"R21-20260105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S150433","article-title":"Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction","volume":"12","author":"Hagen","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R22-20260105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4103\/ijo.IJO_1244_17","article-title":"Oral azithromycin and oral doxycycline for the treatment of meibomian gland dysfunction: A 9-month comparative case series","volume":"67","author":"De Benedetti","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R23-20260105","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00417-019-04322-1","article-title":"Efficacy of azithromycin 1.5% eyedrops versus oral doxycycline in meibomian gland dysfunction: A randomized trial","volume":"257","author":"Satitpitakul","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-20260105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/ICO.0000000000002233","article-title":"The role of topical azithromycin in the treatment of meibomian gland dysfunction","volume":"39","author":"Ciloglu","year":"2020","journal-title":"Cornea"},{"key":"R25-20260105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/ICL.0000000000000729","article-title":"Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis","volume":"47","author":"Arita","year":"2021","journal-title":"Eye Contact Lens"},{"key":"R26-20260105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/jop.2022.0186","article-title":"Effect of treatment with topical azithromycin or oral doxycycline on tear film thickness in patients with meibomian gland dysfunction: A randomized controlled trial","volume":"39","author":"Schlatter","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"R27-20260105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamaophthalmol.2023.0302","article-title":"Pulsed oral azithromycin versus 6-week oral doxycycline for moderate to severe meibomian gland dysfunction: A randomized clinical trial","volume":"141","author":"Upaphong","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R28-20260105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1444-0938.2010.00540.x","article-title":"Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis","volume":"94","author":"Opitz","year":"2011","journal-title":"Clin Exp Optom"},{"key":"R29-20260105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","article-title":"Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: A comparative clinical and spectroscopic pilot study","volume":"32","author":"Foulks","year":"2013","journal-title":"Cornea"},{"key":"R30-20260105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10384-024-01079-x","article-title":"Efficacy and safety of topical azithromycin therapy in patients with blepharitis and meibomian gland function","volume":"68","author":"Shimazaki","year":"2024","journal-title":"Jpn J Ophthalmol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:08Z","timestamp":1787068088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-25-00109","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}